BR112016014115A2 - - Google Patents
Info
- Publication number
- BR112016014115A2 BR112016014115A2 BR112016014115A BR112016014115A BR112016014115A2 BR 112016014115 A2 BR112016014115 A2 BR 112016014115A2 BR 112016014115 A BR112016014115 A BR 112016014115A BR 112016014115 A BR112016014115 A BR 112016014115A BR 112016014115 A2 BR112016014115 A2 BR 112016014115A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198338 | 2013-12-19 | ||
| PCT/EP2014/078384 WO2015091741A1 (en) | 2013-12-19 | 2014-12-18 | Antibacterial 1h-indazole and 1h-indole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016014115A2 true BR112016014115A2 (pt) | 2017-08-08 |
| BR112016014115A8 BR112016014115A8 (pt) | 2017-12-26 |
Family
ID=49880464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016014115A BR112016014115A8 (pt) | 2013-12-19 | 2014-12-18 | Derivados antibacterianos de 1h-indazol e 1hindol |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9624206B2 (pt) |
| EP (1) | EP3083567B1 (pt) |
| JP (1) | JP6407288B2 (pt) |
| KR (1) | KR20160098503A (pt) |
| CN (1) | CN105829288B (pt) |
| AR (1) | AR100032A1 (pt) |
| AU (1) | AU2014368619B2 (pt) |
| BR (1) | BR112016014115A8 (pt) |
| CA (1) | CA2933604A1 (pt) |
| CL (1) | CL2016001524A1 (pt) |
| EA (1) | EA030730B1 (pt) |
| ES (1) | ES2666130T3 (pt) |
| IL (1) | IL246201A0 (pt) |
| MA (1) | MA39189A1 (pt) |
| MX (1) | MX360983B (pt) |
| PH (1) | PH12016501102A1 (pt) |
| PL (1) | PL3083567T3 (pt) |
| SG (1) | SG11201605014YA (pt) |
| TR (1) | TR201807881T4 (pt) |
| TW (1) | TW201609641A (pt) |
| WO (1) | WO2015091741A1 (pt) |
| ZA (1) | ZA201604968B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
| AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
| MX2016014989A (es) | 2014-05-16 | 2017-03-31 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de quinazolina-4 (3h)-ona. |
| CA2963875A1 (en) | 2014-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | Antibacterial benzothiazole derivatives |
| AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
| CN107922433A (zh) * | 2015-08-28 | 2018-04-17 | 爱杜西亚药品有限公司 | 抗菌环化吡咯烷‑2‑酮衍生物 |
| AR105848A1 (es) * | 2015-08-31 | 2017-11-15 | Actelion Pharmaceuticals Ltd | Derivados heterocíclicos antibacterianos |
| AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
| CA3024756A1 (en) * | 2016-05-17 | 2017-11-23 | Idorsia Pharmaceuticals Ltd | 6-(buta-1,3-diyn-1-yl)benzo[d]thiazole derivatives |
| TW201906819A (zh) | 2017-05-25 | 2019-02-16 | 日商大正製藥股份有限公司 | 新穎之咪唑衍生物 |
| WO2019086452A1 (en) * | 2017-10-31 | 2019-05-09 | Idorsia Pharmaceuticals Ltd | Antibacterial heteroaromatic compounds |
| CN113666860B (zh) * | 2020-05-14 | 2024-03-15 | 鲁南制药集团股份有限公司 | 一种7-乙基色醇的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2549159T3 (es) | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | Derivados de bencimidazol N3-alquilados como inhibidores de MEK |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| ES2400689T3 (es) | 2004-10-18 | 2013-04-11 | Amgen, Inc | Compuestos de tiadiazol y métodos de uso |
| BRPI0609719B8 (pt) | 2005-03-23 | 2021-05-25 | Hoffmann La Roche | derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2 |
| TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| EP2432468A2 (en) | 2009-05-20 | 2012-03-28 | Ardea Biosciences, Inc. | Methods of modulating uric acid levels |
| JP5671545B2 (ja) | 2009-10-13 | 2015-02-18 | ファイザー・インク | 抗菌薬として有用なｃ結合ヒドロキサム酸誘導体 |
| PL2512474T3 (pl) | 2009-12-16 | 2015-03-31 | Pfizer | N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| EP2638006A1 (en) | 2010-11-10 | 2013-09-18 | Achaogen, Inc. | Hydroxamic acid derivatives and their use in the treatment of bacterial infections |
| JP2014501274A (ja) | 2011-01-03 | 2014-01-20 | ハンミ ファーム． シーオー．， エルティーディー． | Ｇタンパク質共役受容体調節のための新規な二環式化合物 |
| UA107423C2 (en) * | 2011-03-07 | 2014-12-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
| DK2694488T3 (en) | 2011-04-08 | 2014-12-15 | Pfizer | Isoxazole derivatives useful as antibacterial SUBSTANCES |
| JP2014514299A (ja) | 2011-04-08 | 2014-06-19 | ファイザー・インク | 抗菌剤として有用なイミダゾール、ピラゾールおよびトリアゾール誘導体 |
| EP2847162A1 (en) | 2012-05-09 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| EP2847168A1 (en) | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
| AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
| MX2016014989A (es) | 2014-05-16 | 2017-03-31 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de quinazolina-4 (3h)-ona. |
-
2014
- 2014-12-18 EA EA201600475A patent/EA030730B1/ru not_active IP Right Cessation
- 2014-12-18 ES ES14812752.5T patent/ES2666130T3/es active Active
- 2014-12-18 BR BR112016014115A patent/BR112016014115A8/pt not_active Application Discontinuation
- 2014-12-18 WO PCT/EP2014/078384 patent/WO2015091741A1/en active Application Filing
- 2014-12-18 AR ARP140104742A patent/AR100032A1/es unknown
- 2014-12-18 TW TW103144395A patent/TW201609641A/zh unknown
- 2014-12-18 MA MA39189A patent/MA39189A1/fr unknown
- 2014-12-18 PL PL14812752T patent/PL3083567T3/pl unknown
- 2014-12-18 JP JP2016541300A patent/JP6407288B2/ja not_active Expired - Fee Related
- 2014-12-18 KR KR1020167019669A patent/KR20160098503A/ko not_active Application Discontinuation
- 2014-12-18 CA CA2933604A patent/CA2933604A1/en not_active Abandoned
- 2014-12-18 MX MX2016007991A patent/MX360983B/es active IP Right Grant
- 2014-12-18 TR TR2018/07881T patent/TR201807881T4/tr unknown
- 2014-12-18 US US15/106,790 patent/US9624206B2/en active Active
- 2014-12-18 EP EP14812752.5A patent/EP3083567B1/en not_active Not-in-force
- 2014-12-18 AU AU2014368619A patent/AU2014368619B2/en not_active Ceased
- 2014-12-18 CN CN201480067976.9A patent/CN105829288B/zh not_active Expired - Fee Related
- 2014-12-18 SG SG11201605014YA patent/SG11201605014YA/en unknown
-
2016
- 2016-06-09 PH PH12016501102A patent/PH12016501102A1/en unknown
- 2016-06-14 IL IL246201A patent/IL246201A0/en unknown
- 2016-06-16 CL CL2016001524A patent/CL2016001524A1/es unknown
- 2016-07-18 ZA ZA2016/04968A patent/ZA201604968B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9624206B2 (en) | 2017-04-18 |
| US20170029411A1 (en) | 2017-02-02 |
| MX2016007991A (es) | 2016-10-07 |
| EA030730B1 (ru) | 2018-09-28 |
| EP3083567A1 (en) | 2016-10-26 |
| JP2017500336A (ja) | 2017-01-05 |
| PH12016501102A1 (en) | 2016-07-11 |
| AU2014368619B2 (en) | 2018-11-22 |
| ES2666130T3 (es) | 2018-05-03 |
| TW201609641A (zh) | 2016-03-16 |
| SG11201605014YA (en) | 2016-07-28 |
| BR112016014115A8 (pt) | 2017-12-26 |
| CA2933604A1 (en) | 2015-06-25 |
| CN105829288B (zh) | 2019-01-15 |
| MX360983B (es) | 2018-11-22 |
| EA201600475A1 (ru) | 2016-11-30 |
| KR20160098503A (ko) | 2016-08-18 |
| CN105829288A (zh) | 2016-08-03 |
| ZA201604968B (en) | 2018-11-28 |
| AU2014368619A1 (en) | 2016-07-28 |
| IL246201A0 (en) | 2016-08-02 |
| MA39189A1 (fr) | 2017-06-30 |
| WO2015091741A1 (en) | 2015-06-25 |
| EP3083567B1 (en) | 2018-03-07 |
| JP6407288B2 (ja) | 2018-10-17 |
| CL2016001524A1 (es) | 2017-01-27 |
| TR201807881T4 (tr) | 2018-06-21 |
| AR100032A1 (es) | 2016-09-07 |
| PL3083567T3 (pl) | 2018-08-31 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |